Pharmacotherapy of bipolar depression: An update

Current Psychiatry Reports

Volumn 8, Issue 6, 2006, Pages 478-488

  Thase, Michael E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; INOSITOL; LAMOTRIGINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NORFLUOXETINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; ALOPECIA; ANORGASMIA; BIPOLAR DEPRESSION; BIPOLAR MANIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DIAGNOSTIC ERROR; DIARRHEA; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG OVERDOSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HIRSUTISM; HUMAN; HYPERTENSION; HYPOMANIA; INCREASED APPETITE; LIBIDO DISORDER; LIPID BLOOD LEVEL; MENSTRUATION DISORDER; MONOTHERAPY; NAUSEA; OVARY POLYCYSTIC DISEASE; PANCREATITIS; PATIENT COMPLIANCE; RAPID CYCLING BIPOLAR DISORDER; RECURRENT DISEASE; RELAPSE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOCIAL DISABILITY; STEVENS JOHNSON SYNDROME; SUICIDE; SUICIDE ATTEMPT; THROMBOCYTE COUNT; TREMOR; UNITED STATES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HUMANS; PRACTICE GUIDELINES; RECURRENCE;

EID: 33845909859     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-006-0055-6     Document Type: Review

References (75)

1. Murray CJ, Lopez AD: Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 1996, 274:740-741.
2. Angst J: Bipolar disorder - a seriously underestimated health burdern. Eur Arch Psychiatry Clin Neurosci 2004, 254:59-60.
3. Kupfer DJ: The increasing medical burden in bipolar disorder. JAMA 2005, 293:2528-2530.
4. Perlis RH, Miyahara S, Marangell LB, et al.: Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2004, 55:875-881.
5. Thase ME: Bipolar depression: issues in diagnosis and treatment. Harvard Rev Psychiatry 2005, 13:257-271.
6. Tondo L, Isacsson G, Baldessarini RJ: Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003, 17:491-511.
7. Kessler RC, Berglund P, Demler O, et al.: Lifetime prevalence and age-of-onset distributions' of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005, 62:593-602.
8. Hirschfeld RM, Calabrese JR, Weissman MM, et al.: Screening for bipolar disorder in the community. J Clin Psychiatry 2003, 64:53-59.
9. Judd LL, Akiskal HS: The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003, 73:123-131.
10. Thase ME: Treatment resistant depression and the bipolar spectrum: recognition and management. Prim Psychiatry 2006, In press.
11. Hirschfeld RM, Lewis L, Vornik LA: Perceptions and impact of bipolar disorder: How far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003, 64:161-174.
12. Judd LL, Akiskal HS, Schettler PJ, et al.: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002, 59:530-537.
13. Judd LL, Akiskal HS, Schettler PJ, et al.: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorders. Arch Gen Psychiatry 2003, 60:261-269.
14. Goodwin FK, Jamison KR: Manic-depressive Illness. London and New York: Oxford University Press; 1990.
15. Hlastala SA, Frank E, Mallinger AG, et al.: Bipolar depression: an underestimated treatment challenge. Depress Anxiety 1997, 5:73-83.
16. Kupfer DJ, Frank E, Grochocinski VJ, et al.: Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatrica 2000, 12:110-114.
17. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980.
18. Akiskal HS, Benazzi F, Perugi G, et al.: Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord 2005, 85:245-258.
19. Akiskal HS: Searching for behavioral indicators of bipolar II in patients presenting with major depressive episodes: the "red sign," the "rule of three" and other biographic signs of temperamental extravagance, activation and hypomania. J Affect Disord 2005, 84:279-290.
20. Akiskal HS, Benazzi F: Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II? J Affect Disord 2005, 84:209-217.
21. Strober M, Carlson G: Predictors of bipolar illness in adolescents with major depression: a follow-up investigation. Adolesc Psychiatry 1982, 10:299-319.
22. Akiskal HS: Developmental pathways to bipolarity: Are juvenile-onset depressions pre-bipolar? J Am Acad Child Adolesc Psychiatry 1995, 34:754-763.
23. Akiskal HS, Maser JD, Zeller PJ, et al.: Switching from "unipolar" to bipolar II. An 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 1995, 52:114-123.
24. Findling RL, Youngstrom EA, McNamara NK, et al.: Early symptoms of mania and the role of parental risk. Bipolar Disord 2005, 7:623-634.
25. Gijsman HJ, Geddes JR, Rendell JM, et al.: Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004, 161:1537-1547.
26. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159:3-50.
27. Keck PE, Perlis RH, Otto MW, et al.: The expert consensus guideline series: treatment of bipolar disorder 2004. Postgrad Med Special Report 2004, December:1-119.
28. Suppes T, Dennehy EB, Swann AC, et al.: Report of the Texas consensus conference panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002, 63:288-299.
29. Ketter TA, Calabrese JR: Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002, 63:146-151.
30. Blanco C, Laje G, Olfson M, et al.: Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002, 159:1005-1010.
31. Thase ME, Sachs GS: Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry 2000, 48:558-572.
32. Nemeroff CB, Evans DL, Gyulai L, et al.: Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001, 158:906-912.
33. Goodwin FK, Fireman B, Simon GE, et al.: Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003, 290:1467-1473.
34. Hunkeler EM, Fireman B, Lee J, et al.: Trends in use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youths, 1994-2003. J Child Adolesc Psychopharmacol 2005, 15:26-37.
35. Davis LL, Bartolucci A, Petty F: Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005, 85:259-266.
36. Swann AC, Bowden CL, Calabrese JR, et al.: Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002, 26:530-536.
37. Gyulai L, Bowden CL, McElroy SL, et al.: Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003, 28:1374-1382.
38. Joffe H, Cohen LS, Suppes T, et al.: Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006, 59:1078-1086.
39. Calabrese JR, Bowden CL, Sachs GS, et al.: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999, 60:79-88.
40. Frye MA, Ketter TA, Kimbrell TA, et al.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000, 20:607-614.
41. Nierenberg AA, Ostacher MJ, Calabrese JR, et al.: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006, 163:210-216.
42. Bowden CL, Calabrese JR, Sachs G, et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003, 60:392-400.
43. Calabrese JR, Bowden CL, Sachs G, et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003, 64:1013-1024.
44. Goodwin GM, Bowden CL, Calabrese JR, et al.: A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004, 65:432-441.
45. Calabrese JR, Suppes T, Bowden CL, et al.: A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000, 61:841-850.
46. Calabrese JR, Sullivan JR, Bowden CL, et al.: Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002, 63:1012-1019.
47. Bowden CL, Asnis GM, Ginsberg LD, et al.: Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004, 27:173-184.
48. Post RM, Frye MA, Denicoff KD, et al.: Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology 1998, 19:206-219.
49. Tohen M, Vieta E, Calabrese J, et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003, 60:1079-1088.
50. Brown EB, McElroy SL, Keck PE, et al.: A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006, 67:1025-1033.
51. Calabrese JR, Keck PE, MacFadden W, et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351-1360.
52. Thase ME, MacFadden W, Weisler RH, et al.: Efficacy of quetiapine monotherapy in bipolar I and II depression: a confirmatory double-blind, placebo-controlled study (the Bolder Il study). J Clin Psychopharmacol 2006, In press.
53. Melkersson K, Dahl ML: Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004, 64:701-723.
54. Newcomer JW, Haupt DW, Flavin KS, et al.: Atypical antipsychotic treatment effects on metabolic outcome. Schizophr Bull 2005, 31:566.
55. Buckley NA, McManus PR: Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. Br Med J 2002, 325:1332-1333.
56. Leverich GS, Altshuler LL, Frye MA, et al.: Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006, 163:232-239.
57. Peet M: Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994, 164:549-550.
58. McIntyre RS, Mancini DA, McCann S, et al.: Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002, 4:207-213.
59. Sachs GS, Lafer B, Stoll AL, et al.: A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994, 55:391-393.
60. Thase ME, Haight BR, Richard N, et al.: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005, 66:974-981.
61. Solhkhah R, Wilens TE, Daly J, et al.: Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention/deficit/ hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol 2005, 15:777-786.
62. Smith D, Dempster C, Glanville J, et al.: Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002, 180:396-404.
63. Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001, 178:234-241.
64. Vieta E, Martinez-Aran A, Goikolea JM, et al.: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002, 63:508-512.
65. Himmelhoch JM, Thase ME, Mallinger AG, et al.: Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991, 148:910-916.
66. Thase ME, Mallinger AG, McKnight D, et al.: Treatment of imipramine resistant recurrent depression, IV: a double-blind, crossover study of tranylcypromine in anergic bipolar depression. Am J Psychiatry 1992, 149:195-198.
67. Beasley CM, Masica DN, Heiligenstein JH, et al.: Possible monoamine oxidase inhibitor-serotonin reuptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993, 13:312-320.
68. Thase ME: Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression. J Clin Psychiatry 2006, 67:671-672.
69. Amsterdam JD, Shults J, Brunswick DJ, et al.: Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. Bipolar Disord 2004, 6:75-81.
70. Amsterdam JD, Brunswick DJ: Antidepressant monotherapy for bipolar type II major depression. Bipolar Disord 2003, 5:388-395.
71. Amsterdam JD, Garcia-Espana F: Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affective Disord 2000, 59:225-229.
72. Kupfer DJ, Carpenter LL, Frank E: Is bipolar II a unique disorder? Compr Psychiatry 1988, 29:228-236.
73. Geddes JR, Burgess S, Hawton K, et al.: Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004, 161:217-222.
74. Sachs GS, Thase ME: Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000, 48:573-581.
75. Altshuler L, Suppes T, Black D, et al.: Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003, 160:1252-1262.